...
blte-img

Belite Bio Inc ADR, Common Stock

BLTE

NAQ

$62.96

-$0.1

(-0.16%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$1.95B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
36.36K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
-1.60
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$31 L
$86.53 H
$62.96

About Belite Bio Inc ADR, Common Stock

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameBLTESectorS&P500
1-Week Return-1.86%-2.06%-0.55%
1-Month Return-23.92%-1.92%2.72%
3-Month Return30.32%-10.4%7.66%
6-Month Return26.81%-4.6%10.15%
1-Year Return40.35%4.06%27.53%
3-Year Return494.52%1.94%32.31%

Financials

Dec '20Dec '21Dec '22Dec '23
Total Revenue----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue17.00K30.00K198.00K399.00K[{"date":"2020-12-31","value":4.26,"profit":true},{"date":"2021-12-31","value":7.52,"profit":true},{"date":"2022-12-31","value":49.62,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit(17.00K)(30.00K)(198.00K)(399.00K)[{"date":"2020-12-31","value":-1700000,"profit":false},{"date":"2021-12-31","value":-3000000,"profit":false},{"date":"2022-12-31","value":-19800000,"profit":false},{"date":"2023-12-31","value":-39900000,"profit":false}]
Gross Margin(Infinity%)(Infinity%)(Infinity%)(Infinity%)[{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}]
Operating Expenses5.74M9.80M12.82M31.67M[{"date":"2020-12-31","value":18.14,"profit":true},{"date":"2021-12-31","value":30.94,"profit":true},{"date":"2022-12-31","value":40.49,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(5.74M)(9.80M)(12.82M)(31.67M)[{"date":"2020-12-31","value":-574300000,"profit":false},{"date":"2021-12-31","value":-979700000,"profit":false},{"date":"2022-12-31","value":-1282100000,"profit":false},{"date":"2023-12-31","value":-3166800000,"profit":false}]
Total Non-Operating Income/Expense(18.00K)136.00K180.00K94.00K[{"date":"2020-12-31","value":-10,"profit":false},{"date":"2021-12-31","value":75.56,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":52.22,"profit":true}]
Pre-Tax Income(5.75M)(9.67M)(12.65M)(31.62M)[{"date":"2020-12-31","value":-575200000,"profit":false},{"date":"2021-12-31","value":-966600000,"profit":false},{"date":"2022-12-31","value":-1264800000,"profit":false},{"date":"2023-12-31","value":-3162300000,"profit":false}]
Income Taxes1.00K126.00K(173.00K)9.00K[{"date":"2020-12-31","value":0.79,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-137.3,"profit":false},{"date":"2023-12-31","value":7.14,"profit":true}]
Income After Taxes(5.75M)(9.79M)(12.47M)(31.63M)[{"date":"2020-12-31","value":-575300000,"profit":false},{"date":"2021-12-31","value":-979200000,"profit":false},{"date":"2022-12-31","value":-1247500000,"profit":false},{"date":"2023-12-31","value":-3163200000,"profit":false}]
Income From Continuous Operations(5.75M)(9.67M)(12.65M)(31.63M)[{"date":"2020-12-31","value":-575300000,"profit":false},{"date":"2021-12-31","value":-966600000,"profit":false},{"date":"2022-12-31","value":-1264800000,"profit":false},{"date":"2023-12-31","value":-3163200000,"profit":false}]
Income From Discontinued Operations----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(5.75M)(9.79M)(12.47M)(31.63M)[{"date":"2020-12-31","value":-575300000,"profit":false},{"date":"2021-12-31","value":-979200000,"profit":false},{"date":"2022-12-31","value":-1247500000,"profit":false},{"date":"2023-12-31","value":-3163200000,"profit":false}]
EPS (Diluted)-(0.20)(0.96)(1.24)[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-20,"profit":false},{"date":"2022-12-31","value":-96,"profit":false},{"date":"2023-12-31","value":-124,"profit":false}]

Ratios

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

BLTE
ROA (LTM) -25.58%
ROE (LTM) -40.04%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

BLTE
Debt Ratio Lower is generally better. Negative is bad. 0.03
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.97

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

BLTE
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 17.36
EV/R 0.00
EV/Ebitda NM

FAQs

What is Belite Bio Inc ADR share price today?

Belite Bio Inc ADR (BLTE) share price today is $62.96

Can Indians buy Belite Bio Inc ADR shares?

Yes, Indians can buy shares of Belite Bio Inc ADR (BLTE) on Vested. To buy Belite Bio Inc ADR from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BLTE stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Belite Bio Inc ADR be purchased?

Yes, you can purchase fractional shares of Belite Bio Inc ADR (BLTE) via the Vested app. You can start investing in Belite Bio Inc ADR (BLTE) with a minimum investment of $1.

How to invest in Belite Bio Inc ADR shares from India?

You can invest in shares of Belite Bio Inc ADR (BLTE) via Vested in three simple steps:

  • Click on Sign Up or Invest in BLTE stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Belite Bio Inc ADR shares
What is Belite Bio Inc ADR 52-week high and low stock price?

The 52-week high price of Belite Bio Inc ADR (BLTE) is $86.53. The 52-week low price of Belite Bio Inc ADR (BLTE) is $31.

What is Belite Bio Inc ADR price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Belite Bio Inc ADR (BLTE) is

What is Belite Bio Inc ADR price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Belite Bio Inc ADR (BLTE) is 17.36

What is Belite Bio Inc ADR dividend yield?

The dividend yield of Belite Bio Inc ADR (BLTE) is 0.00%

What is the Market Cap of Belite Bio Inc ADR?

The market capitalization of Belite Bio Inc ADR (BLTE) is $1.95B

What is Belite Bio Inc ADR’s stock symbol?

The stock symbol (or ticker) of Belite Bio Inc ADR is BLTE

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top